BRPI0717822A2 - Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. - Google Patents
Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.Info
- Publication number
- BRPI0717822A2 BRPI0717822A2 BRPI0717822-0A2A BRPI0717822A BRPI0717822A2 BR PI0717822 A2 BRPI0717822 A2 BR PI0717822A2 BR PI0717822 A BRPI0717822 A BR PI0717822A BR PI0717822 A2 BRPI0717822 A2 BR PI0717822A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prophylaxy
- receptors
- diseases
- modulation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06121749 | 2006-10-04 | ||
| PCT/EP2007/060090 WO2008040649A2 (en) | 2006-10-04 | 2007-09-24 | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0717822A2 true BRPI0717822A2 (pt) | 2013-11-12 |
Family
ID=39166552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717822-0A2A BRPI0717822A2 (pt) | 2006-10-04 | 2007-09-24 | Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7691863B2 (pt) |
| EP (1) | EP2076499B1 (pt) |
| JP (1) | JP5064506B2 (pt) |
| KR (1) | KR101114704B1 (pt) |
| CN (1) | CN101522644B (pt) |
| AR (1) | AR063101A1 (pt) |
| AT (1) | ATE467622T1 (pt) |
| AU (1) | AU2007304363B2 (pt) |
| BR (1) | BRPI0717822A2 (pt) |
| CA (1) | CA2664621A1 (pt) |
| CL (1) | CL2007002834A1 (pt) |
| DE (1) | DE602007006531D1 (pt) |
| ES (1) | ES2344128T3 (pt) |
| IL (1) | IL197763A0 (pt) |
| MX (1) | MX2009003316A (pt) |
| PE (1) | PE20080855A1 (pt) |
| TW (1) | TW200825065A (pt) |
| WO (1) | WO2008040649A2 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| EP2074096B1 (en) * | 2006-10-04 | 2012-06-27 | F. Hoffmann-La Roche AG | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
| US7897621B2 (en) * | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
| US8088920B2 (en) * | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| WO2014086807A1 (en) * | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Novel pyrazine derivatives as cb2 receptor agonists |
| LT2928881T (lt) * | 2012-12-07 | 2018-06-11 | F. Hoffmann-La Roche Ag | Nauji piridino dariniai |
| SG11201504475QA (en) * | 2012-12-07 | 2015-07-30 | Hoffmann La Roche | Pyridine-2-amides useful as cb2 agonists |
| ES2643058T3 (es) * | 2012-12-07 | 2017-11-21 | F. Hoffmann-La Roche Ag | Piridina-2-amidas útiles como agonistas de CB2 |
| AU2015239537B2 (en) * | 2014-04-04 | 2019-04-04 | Eidgenoessische Technische Hochschule Zuerich | 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN109384734B (zh) * | 2017-08-14 | 2023-04-11 | 上海科胜药物研发有限公司 | 一种塞尔西帕中间体的制备方法 |
| EP3814328B1 (en) | 2018-06-27 | 2026-03-11 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine compounds as inhibitors of cannabinoid receptor 2 |
| EP3814337B1 (en) * | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| MX2020012760A (es) | 2018-06-27 | 2021-03-25 | Hoffmann La Roche | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| WO2023082145A1 (en) * | 2021-11-11 | 2023-05-19 | 4B Technologies (Suzhou) Limited | Intermediate compound of quinoxaline and preparation process thereof |
| WO2026017100A1 (zh) * | 2024-07-19 | 2026-01-22 | 药捷安康(南京)科技股份有限公司 | Alox抑制剂及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5738778A (en) * | 1980-08-18 | 1982-03-03 | Kyowa Gas Chem Ind Co Ltd | Novel cyanopyrazine derivative |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| CA2517291C (en) * | 2003-03-19 | 2012-05-08 | Exelixis, Inc. | Ortho-substituted aryl and heteroaryl tie-2 modulators and methods of use |
| EP1641779A1 (en) | 2003-06-18 | 2006-04-05 | AstraZeneca AB | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| ES2326280T3 (es) | 2005-04-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | Derivados de piridin-3-carboxamida como agonistas inversos de cb1. |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
-
2007
- 2007-09-24 WO PCT/EP2007/060090 patent/WO2008040649A2/en not_active Ceased
- 2007-09-24 KR KR1020097008997A patent/KR101114704B1/ko not_active Expired - Fee Related
- 2007-09-24 BR BRPI0717822-0A2A patent/BRPI0717822A2/pt not_active IP Right Cessation
- 2007-09-24 EP EP07820497A patent/EP2076499B1/en not_active Not-in-force
- 2007-09-24 CN CN2007800372430A patent/CN101522644B/zh not_active Expired - Fee Related
- 2007-09-24 DE DE602007006531T patent/DE602007006531D1/de active Active
- 2007-09-24 MX MX2009003316A patent/MX2009003316A/es active IP Right Grant
- 2007-09-24 ES ES07820497T patent/ES2344128T3/es active Active
- 2007-09-24 JP JP2009530841A patent/JP5064506B2/ja not_active Expired - Fee Related
- 2007-09-24 US US11/903,581 patent/US7691863B2/en not_active Expired - Fee Related
- 2007-09-24 CA CA002664621A patent/CA2664621A1/en not_active Abandoned
- 2007-09-24 AU AU2007304363A patent/AU2007304363B2/en not_active Ceased
- 2007-09-24 AT AT07820497T patent/ATE467622T1/de active
- 2007-10-02 CL CL200702834A patent/CL2007002834A1/es unknown
- 2007-10-02 AR ARP070104363A patent/AR063101A1/es unknown
- 2007-10-02 TW TW096136934A patent/TW200825065A/zh unknown
- 2007-10-03 PE PE2007001334A patent/PE20080855A1/es not_active Application Discontinuation
-
2009
- 2009-03-23 IL IL197763A patent/IL197763A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007304363A1 (en) | 2008-04-10 |
| CN101522644B (zh) | 2013-04-24 |
| PE20080855A1 (es) | 2008-06-28 |
| KR20090084842A (ko) | 2009-08-05 |
| EP2076499B1 (en) | 2010-05-12 |
| CL2007002834A1 (es) | 2008-05-16 |
| WO2008040649A3 (en) | 2008-05-29 |
| AR063101A1 (es) | 2008-12-30 |
| IL197763A0 (en) | 2009-12-24 |
| KR101114704B1 (ko) | 2012-03-14 |
| JP5064506B2 (ja) | 2012-10-31 |
| ES2344128T3 (es) | 2010-08-18 |
| EP2076499A2 (en) | 2009-07-08 |
| US20080085905A1 (en) | 2008-04-10 |
| WO2008040649A2 (en) | 2008-04-10 |
| TW200825065A (en) | 2008-06-16 |
| DE602007006531D1 (de) | 2010-06-24 |
| MX2009003316A (es) | 2009-04-09 |
| CA2664621A1 (en) | 2008-04-10 |
| JP2010505788A (ja) | 2010-02-25 |
| US7691863B2 (en) | 2010-04-06 |
| AU2007304363B2 (en) | 2013-01-17 |
| CN101522644A (zh) | 2009-09-02 |
| ATE467622T1 (de) | 2010-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0821299A2 (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição. | |
| DK1984357T3 (da) | 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| WO2007095638A3 (en) | Boron-containing small molecules as anti-inflammatory agents | |
| BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| BRPI0718339A2 (pt) | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina | |
| BRPI0717753A2 (pt) | Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição. | |
| BRPI0906786A2 (pt) | Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit. | |
| EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
| BRPI0716703A2 (pt) | "composiÇço, fluidos funcionais e processo de preparaÇço de uma composiÇço" | |
| BRPI0813341A2 (pt) | " uso de compostos, composições curáveis, e, uso de composições curáveis ". | |
| BRPI0919918A2 (pt) | Composto de vanilina e de etilvanilina, processo de preparação do mesmo, composição, e, aplicação do composto. | |
| DE602006010132D1 (de) | Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol | |
| BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
| CL2007003352A1 (es) | Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen | |
| PT2056805E (pt) | Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular | |
| EA201000258A1 (ru) | Новые гербициды | |
| DE502007005902D1 (de) | -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate | |
| BRPI0720323A2 (pt) | composto, método de tratamento, composição farmacêutica e uso do composto | |
| BRPI0909566A2 (pt) | Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante | |
| BRPI0814346A2 (pt) | Uso de imidazoquinolinas para o tratamento de doenças dependentes de egfr ou doenças que adquiriram resistência a agentes que são direcionados aos membros da família de egfr. | |
| BRPI0718999A2 (pt) | Pirazois substituídos, composições que os contêm, processo de produção e utilização | |
| BRPI0812458A2 (pt) | " processo de revestimento de passagem ". | |
| BRPI0821197A2 (pt) | Composto, composição farmacêutica, uso de um composto, processo, e, intermediário. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |